Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Gynecologic 2

Conditions

Uterine Cervical Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 233Carboplatin 217Bevacizumab 139Cisplatin 136pembrolizumab 89Gemcitabine 69olaparib 54Docetaxel 47Topotecan 44Radiotherapy 43liposomal doxorubicin 41Taxes 41niraparib 38Cyclophosphamide 36Doxorubicin 30Drug Therapy 29Letrozole 28Nivolumab 27Magnetic Resonance Spectroscopy 25Immunoglobulin G 25Disulfides 24Oxaliplatin 23Albumin-Bound Paclitaxel 23durvalumab 22apatinib 21Etoposide 21Brachytherapy 21lenvatinib 20camrelizumab 20Specimen Handling 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × belotecan × Gynecologic × Clear all
NCT01630018 2016-09-22

Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial

Chong Kun Dang Pharmaceutical

Phase 2 Completed
141 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

NCT00430144 2012-04-26

Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix

National Cancer Center, Korea

Phase 2 Completed
16 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡